Home
Description here
-
31:28Watch VideoFlipping the Funnel in Patient Recruitment to Accelerate Enrollment Timelines
-
Read FlipbookSomething Has to Give: The Current Unsustainable Approach to Safety Reporting Puts Trials and Patients at Risk
Something Has to Give: The Current Unsustainable Approach to Safety Reporting Puts Trials and Patients at Risk
-
Read FlipbookQuality First: Using Data to Inform Site Selection in CNS
WCG MedAvante-ProPhase espouses a rather simple philosophy: minimize variability, generate cleaner data.
-
32:54Watch VideoReinventing Site Feasibility: Moving from Simple Survey to Relationship Management
-
44:43Watch VideoClinical Trials in the Era of Precision Medicine
-
Read PostSite Score Card: Expert Tips for Moving Up the Ranks
How can a site move up the selection list and participate in these trials? It’s as simple as one word: metrics.
-
Read Flipbook
Six Practices of High Performing Clinical Research Sites
Learn what high-performing research sites have in common, and what makes sponsors return to them again and again.
-
Read Flipbook
Not Like Everyone Else: Unique Challenges for Small & Emerging Biopharma Companies
Small and emerging biopharmas are conducting almost 50% of clinical trials in the U.S., often with lean teams, resources and infrastructure. Learn how to reduce the pressure on teams and timelines.
-
From the "Ask the IRB Experts" blog
section -
Read PostQuestion: What are the requirements for submitting protocol deviations?
Some deviations from the IRB approved protocol are planned while others are unintentional or unplanned. The FDA and HHS (45 CFR §46.103(b)(4) and 21 CFR §56.108(a)(4)), position is that...
-
Read PostQuestion: Does the IRB need to review news stories?
The local newspaper is planning to run a story on a new clinical trial that will highlight the development of an exciting new drug and the work done by our principal investigator...
-
Read PostQuestion: When can research participants be paid?
As a sponsor, what do the regulations say about paying research subjects? What are acceptable practices for compensating subjects for participating in a clinical trial?
-
New Blog: "Ask the IRB Experts"
Visit Blog -
Recent Videos
section -
13:58Watch VideoThe Role of Expert Committees: An interview with Dr. Seltzer
What’s the role of expert committees today? What’s happening on the regulatory side? Dr. Seltzer, Chief Scientific Officer of WCG Clinical, shared his insights on expert committees during a recent...
-
32:32Watch VideoEliminating the Headache of Global Safety Reporting to Investigators and Ethics Committees
-
30:39Watch VideoPortfolio Based Data-Driven Site Selection
-
52:22Watch VideoRecruiting Patients & Time Management: Top Tips for Dealing with the Most Critical Resource in Research
Learn how to engage sites more effectively with the appropriate recruitment resources, use dedicated staff to manage recruitment efforts, and eliminate bottlenecks and expedite recruitment timelines.
-
Drug Safety Services & Technology
section -
Read Flipbook
How Roche Optimized its Global Safety Reporting Process for Clinical Trials
Roche recognized several major challenges that its CTSP 2.0 system needed to address.
-
Read FlipbookBy the Numbers: Six Challenges to Enrollment, One Customized Solution
-
Read Flipbook
OhioHealth Case Study
Dissatisfied with its electronic IRB research management solution, OhioHealth Research & Innovation Institute searched for a solution to improve compliance, efficiency, customer service, and cost.
-
Read FlipbookHow a Sponsor Secured 200 High-Performing PI's in a New TA in Just 5 Days
-
Whitepapers
section -
Read Flipbook
Removing Barriers: Reimbursement and Compensation for Participation in Oncology Clinical Trials
The impact of participant payments on clinical trial recruitment.
-
Loading More...
